Tyrosine kinase inhibitors may change the metastatic pattern

J BUON. 2013 Apr-Jun;18(2):544.

Authors

M A N Sendur¹, S Aksoy, N Y Ozdemir, N Zengin

Affiliation

¹ Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.

PMID: 23818376

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / enzymology
Adenocarcinoma / secondary*
Adenocarcinoma of Lung
Antineoplastic Agents / therapeutic use*
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / metabolism
Erlotinib Hydrochloride
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / pathology*
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use*
Skin Neoplasms / secondary*
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors